Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer

Xiong, Yang; Zhao, Yi; Miao, Lei; Lin, Chii M.; Huang, Leaf

doi:10.1016/j.jconrel.2016.11.005

Cited by 78 publications

(43 citation statements)

References 38 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may also indicate that HPNs targeted tumor cells not only passively through the EPR effect, but also actively via binding affinity to CD44 in the xenograft (Xiong et al ., 2016). …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Kim

Park

2017

Biomolecules & Therapeutics

View full text Add to dashboard Cite

Paclitaxel (PTX) is a effectively chemotherapeutic agent which is extensively able to treat the non-small cell lung, pancreatic, breast and other cancers. But it is a practically insoluble drug with water solubility less than 1 μg/mL, which restricts its therapeutic application. To overcome the problem, hyaluronic acid-complexed paclitaxel nanoemulsions (HPNs) were prepared by ionic complexation of paclitaxel (PTX) nanoemulsions and hyaluronic acid (HA) to specifically target non-small cell lung cancer. HPNs were composed of dl-α-tocopheryl acetate, soybean oil, polysorbate 80, ferric chloride, and HA and fabricated by high-pressure homogenization. The HPNs were 85.2 ± 7.55 nm in diameter and had a zeta potential of −35.7 ± 0.25 mV. The encapsulation efficiency was almost 100%, and the PTX content was 3.0 mg/mL. We assessed the in vivo antitumor efficacy of the HPNs by measuring changes in tumor volume and body weight in nude mice transplanted with CD44-overexpressing NCI-H460 xenografts and treated with a bolus dose of saline, Taxol®, PTX nanoemulsions (PNs), or HPNs at a dose of 25 mg/kg. Suppression of cancer cell growth was higher in the PN- and HPN-treated groups than in the Taxol® group. In particular, HPN treatment dramatically inhibited tumor growth, likely because of the specific tumor-targeting affinity of HA for CD44-overexpressed cancer cells. The loss of body weight and organ weight did not vary significantly between the groups. It is suggest that HPNs should be used to effective nanocarrier system for targeting delivery of non-small cell lung cancer overexpressing CD44 and high solubilization of poorly soluble drug.

show abstract

“…This may also indicate that HPNs targeted tumor cells not only passively through the EPR effect, but also actively via binding affinity to CD44 in the xenograft (Xiong et al ., 2016). …”

Section: Resultsmentioning

confidence: 99%

“…Tumors were measured with vernier calipers, and tumor size was calculated from the length and width according to the following formula (Liu et al ., 2011a; Yang et al ., 2013; Xiong et al ., 2016):…”

Section: Methodsmentioning

confidence: 99%

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Kim

Park

2017

Biomolecules & Therapeutics

View full text Add to dashboard Cite

show abstract

“…VEGF and Bcl-2) [71]. Based on this, metformin has been further exploited to conjugate with hydrophobic lipid chains to form cationic lipid-like drugs, and thus co-encapsulating siRNA or DNA for combinatory or synergistic purposes [135, 140] (Figure 4). …”

Section: Combination Of Sirna/chemodrugs In a Single Carriermentioning

confidence: 99%

Nanoformulations for combination or cascade anticancer therapy

Miao

Guo

Lin

et al. 2017

Advanced Drug Delivery Reviews

Self Cite

154

View full text Add to dashboard Cite

Nanoparticle drug formulations have been extensively investigated, developed, and in some cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can circumvent the issue of treatment resistance and may be essential for effective anti-cancer therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier presents a challenge due to differences in solubility, molecular weight, functional groups and encapsulation conditions between the two drugs. This review discusses cellular and microenvironment mechanisms behind treatment resistance and nanotechnology-based solutions for effective anti-cancer therapy. Co-loading or cascade delivery of multiple drugs using of polymeric nanoparticles, polymer-drug conjugates and lipid nanoparticles will be discussed along with lipid-coated drug nanoparticles developed by our lab and perspectives on combination therapy.

show abstract

“…Polymer-cisplatin nanoparticles showed the highest anticancer effectiveness between all treatment groups due to core-membrane nanoparticles co-encapsulated with cisplatin (conjugated with polyglutamic acid (PGA) as anionic PGA-cisplatin) and metformin (as cationic polymer called polymer) and the synergistic effect of these two complexes (35).…”

Section: Nano-compound Based On the Metformin-cisplatin Combinationmentioning

confidence: 99%

Nephroprotection and chemotherapy sensitivity impact of metformin during cisplatin therapy; an updated review

Sepahi

Mehrabi²,

Valizadeh

et al. 2019

J Nephropathol

View full text Add to dashboard Cite

Chemotherapy has been accepted as the most common choice for cancer treatment. However, chemotherapy-induced toxicity and chemotherapy resistance are the two challenging barriers to the treatment. Metformin is a safe, inexpensive, and the first line drug to treat type II diabetes. It has also a significant anti-tumor effect with a selective cytotoxic efficacy on cancer stem cells. It also has renoprotective efficacy. The current study contributes to incorporating metformin to chemotherapeutic agents to develop treatment efficiency and reduce the chemotherapy-induced side-effects (such as toxicity and resistance) and also to benefit the nephroprotective impact of this drug.

show abstract

Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer

Cited by 78 publications

References 38 publications

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Nanoformulations for combination or cascade anticancer therapy

Nephroprotection and chemotherapy sensitivity impact of metformin during cisplatin therapy; an updated review

Contact Info

Product

Resources

About